Cell Culture in an important tool for research and development within the life science industry. The global
3D Cell Culture Market market is valued at USD 1069.28 Million and is expected to grow with a CAGR of 25.31% over the forecast period. Researchers globally are realizing the potential of
3D cell culture for various applications, including models for personalized medicine, complex and multi-cell type models, translation and clinical and industrial applications.
Over the past few years,
3D Cell Culture has gained momentum within the pharmaceutical industry due to the benefits that this model offers for in vitro applications patient-derived tissues, drug discovery, predictivity and validation, and safety and toxicity.
Our
3D Cell Culture conference will explore advances of organ and lab-on-a-chip, microphysiological systems, applications of technology and case studies, imaging, high throughput screening and advances in 3D cell culture models which make up core components within the
3D Cell Culture field.
Benefits of Attending
- Learn from leading pharma companies to benchmark against their applications of 3D technology
- Explore case studies of 3D cell culture, high throughput screening, imaging and microphysiological systems in industry
- Hear about the latest technology advances allowing 3D bioprinting to revolutionize in vitro models
- Network with the key industry players developing the use of bioprinting as part of their R&D
- Understand novel applications of 3D bioprinting for in vitro models, regenerative medicine and screening
Who should attend
Executives, Directors, VPs, Heads, Principals, Managers of:
- Cell Technology
- Lab Head Lead Discovery
- High Throughput Screening
- Research and Development
- Disease Models
- Cell Biology & Tissue Engineering
- Translational Science
- Complex In Vitro Models
- Cell and Molecular Scientist
- Systems Biology
- Drug Discovery
Plus a Pre-Conference Focus Day: 18th February
3D BioprintingChair: Jason Ekert, Head of Complex In Vitro Models,GSK
Speakers
- Alessandro Fiorenzano, Postdoctoral fellow , Lund University
- Alexander D. Graham, Investigator Scientist, MRC Harwell Institute
- Andrea Leonard, Senior Scientist, TreeFrog Therapeutics
- Asli Akidil, Cell and Molecular Scientist, AstraZeneca
- Ellen J Wehrens, Scientific Writer, Princess Maxima Center
- Floriane Groell, (Research Associate of the) Biopharmaceutical Sciences department, University of Geneva
- Hilary Pollard, Product Manager - Cell Based Assays, Promega UK Ltd
- Jason Ekert, Head of Complex In Vitro Models, GlaxoSmithKline
- Kenny Dalgarno, Professor of Manufacturing Engineering, Newcastle University
- Leonard Both, Senior Quality Assessor, Biologicals/Biotechnology Unit, Medicines & Healthcare products Regulatory Agency (MHRA)
- Michele Zagnoni, Senior Lecturer, University Of Strathclyde
- Natalie Abts, Head of Human Factors Engineering, Genentech
- Philip Hewitt, UK and Eurotox Registered Toxicologist, Global Head of Early Investigative Toxicology, Merck Healthcare KGaA
- Rhiannon David, Associate Principal Scientist, AstraZeneca
- Samuel Jackson, Programme Manager, Disease Models, NC3Rs
- Simone Stahl, Associate Principal Scientist, AstraZeneca
- Stefan Przyborski, Professor of Cell Technology, Durham University
- Therese Kallur, Director Business Development, BioLamina AB
- Veronique Barban, Expert Virology, Sanofi Pasteur
- Wendy Rowan, Scientific Director, GSK
Please fill in your name and email to receive the Conference Agenda of this event.
Venue
Copthorne Tara Hotel
Scarsdale Pl, Kensington, W8 5SY
London, UK
